In vivo targeting by liposomes

Area of Science:

• Biotechnology
• Nanomedicine
• Drug Delivery Systems

Background:

• Conventional immunoliposomes face challenges in targeting specific anatomical compartments.
• Pendant-type PEG-immunoliposomes (Type C) offer a novel approach for targeted delivery.
• PEGylation strategies are crucial for improving liposome circulation time and targeting efficiency.

Purpose of the Study:

• To evaluate the targeting efficacy of newly developed pendant-type PEG-immunoliposomes (Type C).
• To assess the potential of Type C immunoliposomes for targeting both lung endothelium and solid tumors.
• To investigate the impact of antibody conjugation site on PEG-liposome targeting.

Main Methods:

• Synthesis of DSPE-PEG-COOH and DPPE-PEG-Mal for liposome functionalization.
• Preparation of small unilamellar liposomes incorporating PEG derivatives.
• Conjugation of specific antibodies (34A, 21B2) and antibody fragments (Fab') to PEG-liposomes.
• In vivo evaluation of lung and solid tumor targeting in mouse models.

Main Results:

• 34A-Type C immunoliposomes exhibited significantly higher binding to mouse lung endothelium compared to conventional immunoliposomes.
• Fab'-Type C immunoliposomes demonstrated low RES uptake, prolonged circulation time, and enhanced accumulation in solid tumors.
• Small Fab'-Type C predominantly utilized passive convective transport through leaky tumor vasculature.

Conclusions:

• Pendant-type PEG-immunoliposomes (Type C) represent a promising platform for targeted drug delivery.
• Type C immunoliposomes show potential for specific targeting of accessible (lung) and less accessible (solid tumor) sites.
• The design of Type C immunoliposomes enhances drug delivery efficiency and therapeutic outcomes.